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ABSTRACT 
The goal of CERVIS is to increase screening for cervical cancer through the development of a 
low-cost, minimally invasive screening procedure for women in low-resource settings that 
requires minimal healthcare expertise. There currently exist two primary screening procedures: 
the Pap smear, primarily used in developed countries, and visual inspection with acetic acid 
(VIA), primarily used in low and middle-income countries (LMICs). Both of these procedures 
require a high degree of healthcare training in order to administer and interpret, and are highly 
invasive, requiring direct interaction with the cervix. Our alternative procedure utilizes a 
particular bacteria, ​Fusobacterium nucleatum​, within the cervicovaginal microbiome that has 
been associated with cervical cancer pathology. Our screening procedure seeks to identify the 
need for further diagnostic testing based on a vaginal swab representative of fusobacteria 
colonization of the vagina. Two modalities, growth media containing colorimetric indicators and 
a qPCR-based assay, are used to qualitatively and quantitatively measure the presence of this 
bacteria. This collection method is less invasive and does not require healthcare expertise, 
therefore allowing for self-administration. Outcomes of testing are measured by determining the 
feasibility of the prototype regarding sensitivity and parameters of bacterial growth, including 
time for incubation, the temperature of incubation, and aerobic exposure time. Further testing 
will include quantifying fusobacteria in a cervical cancer patient sample and establishing exact 
temperature ranges of incubation and incubation time.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
Globally, cervical cancer ranks fourth in incidence and in cancer-related mortality among 
women, with the majority of cases occurring in low and middle-income countries (LMICs) 
(WHO, 2019). These high incidence and mortality rates are due to delayed diagnosis, which 
means that cervical cancer often goes undetected for several years. The WHO states that 90% of 
those cervical cancer-related deaths occur in LMICs, many of which could be prevented by early 
screening and diagnosis (WHO, 2019). Human Papillomavirus (HPV) is the most common risk 
factor for cervical cancer, and proper implementation of an HPV vaccine helps to prevent this 
disease (Liu & Richardson, 1987). However, while this vaccine is widely used in developed 
countries, it is not implemented on a national level in many LMICs, and even if programs exist 
these are not effective (Nakisige, 2017). Vaccines are in the process of being implemented but 
would be ideally administered to girls in their pre-teenage years, and as such the effects of such a 
vaccine would take many years to be able to see results. Furthermore, to decrease the incidence 
of the disease, it is still necessary to address prevention factors while also pursuing cervical 
cancer screening, diagnostic and treatment measures. 
 
Additional prevention methods that enable detection of precancerous changes before progression 
to invasive disease are also being developed to help reduce the prevalence of cervical cancer 
cases (​Finocchario-Kessler, 2016)​. Screening is a very common prevention method, but in 
LMICs, the screening rates remain very low (Gyawali, 2015; Runge, 2019). This is often because 
there are shortages in the necessary supplies to perform these screening tests and a lack of trained 
healthcare personnel to administer these tests (PATH, 2019). Cervical cancer education is an 
additional preventative measure to help inform women of the risks and proper safety practices 
surrounding unsafe sex, but many LMICs currently lack this sort of education. 
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1.2 Significance of Project 
Although cervical cancer is the 4th most common cancer in women worldwide, there are 
currently no low-cost, minimally-invasive screening tests available. Due to the prevalence of 
cervical cancer, the HPV vaccine is not simply a replacement for screening. Implementing the 
HPV vaccine is a proactive prevention measure, whereas screening is reactionary to the 
development of cervical cancer, preventing its progression to later stages. Current cervical cancer 
screening procedures identify DNA and protein biomarkers from cervical samples but are 
expensive, difficult to administer, and often invasive. These factors limit test feasibility in 
low-resource areas, creating a need for new screening technologies.  
 
Team CERVIS aims to increase screening in Uganda by developing a low-cost, 
minimally-invasive screening test that can be self-administered and requires minimal healthcare 
expertise. Last year’s test created a prototype for this screening test, and this year our focus is on 
determining the feasibility of that prototype by determining its sensitivity and optimal 
implementation parameters.  
 
1.3 Proposed Goals 
Team CERVIS, a group of undergraduate students from Santa Clara University departments of 
Bioengineering and Public Health, aims to build on a promising prototype designed to detect the 
presence of fusobacteria on a vaginal swab. Fusobacteria is an anaerobic bacteria found in the 
cervical and vaginal microbiomes that is found in increased concentrations in cervical cancer 
(Audirae Chalifour et al., 2016). The prototype contains media that will change color due to a 
reaction with fusobacteria present on a vaginal swab. While last year’s team successfully proved 
that the media was specific to fusobacteria, it is still unclear whether the prototype is sensitive 
enough to detect the amount of fusobacteria present in vaginal samples of patients with cervical 
cancer. Furthermore, this year, team CERVIS ​explored the feasibility of implementing this 
prototype, including testing the sensitivity of the media along with determining optimal 
implementation parameters. 
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CHAPTER 2: PROJECT OVERVIEW 
 
2.1 Target Population 
The development of the prototype requires a targeted population to establish a deployment 
strategy and to measure the current impacts of cervical cancer and its preventative strategies. Our 
chosen target population is women in Uganda, where one of the highest incidences of cervical 
cancer in the world is observed, as well as a low screening rate (Black, 2019). Uganda lacks 
many primary and secondary preventative methods to help reduce cases of cervical cancer. 
Uganda is a Sub-Saharan country in Eastern Africa, with a population of nearly 32 million. Each 
year, about 40.5 in 100,000 Ugandan women die of cervical cancer compared to 6.8, the global 
average (Black, 2019). Cultural reticence to seek routine invasive pelvic examinations also 
prevents women from seeking treatment until the disease has progressed to severe, symptomatic 
stages (WHO Training Guide 2015). Up to half of women diagnosed with late-stage cervical 
cancer die within 3 years of diagnosis (Wabinga, et al., 2000), and up to 80 percent of those 
women die within 5 years (Gondos, et al., 2005). Increased, minimally invasive screening could 
prevent such deaths from occurring. 
 
Presently, despite Uganda’s nationally-implemented HPV vaccine program, efforts by the 
Ministry of Health have been uncoordinated and had limited success (Nakisige et.al., 2017). 
Furthermore, in 2016, only 4.8% of women have been screened (Campos et.al., 2017). 
Successful implementation of an HPV vaccine program would greatly decrease the incidence of 
cervical cancer, but screening and diagnostic technology are still required in order to effectively 
combat mortality rates from this disease.​ ​Finally, our team currently has connections to a 
non-governmental organization (NGO), Rose Academies, and several clinics there. Therefore, it 
makes it an ideal location to develop a deeper understanding of our target population’s needs, 
and could also establish a relationship for future product deployment. 
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2.1.1 Parameters for Deployment 
There are several parameters that need to be considered prior to deployment of the prototype, but 
a select few were determined to be the most pressing to assess feasibility given the limits of 
conditions in Uganda. Currently, women in rural areas travel to receive healthcare or have 
outreach teams visit them to provide healthcare services (Jeronimo et al., 2014). We wanted to 
establish a baseline incubation time for the color change to evaluate the feasibility of our 
prototype in the field. Incubation temperature of the fusobacteria is another major factor to 
properly produce an indicative dark gray color. Many areas may not have access to an incubator 
to maintain the standard temperature of incubation for fusobacteria, so this parameter is explored 
throughout our experiments to determine whether or not an incubator is a necessary element for 
proper prototype functionality. Finally, due to the anaerobic nature of our target bacteria, we 
have considered aerobic exposure as an important parameter to analyze for feasibility. 
Determining how long a swab can be exposed to air prior to insertion into the media will help to 
develop a proper protocol for healthcare clinicians administering this test. Cervical cancer is a 
malignant and proliferative disease in countries like Uganda, but Team CERVIS aims to reduce 
its severe incidence and mortality that women suffer. 
 
2.2 Review of the Field: Current Detection Methods 
The key to preventing and addressing cervical cancer development is preventative medicine and 
routine screenings. Current guidelines for women recommend annual cervical cancer screening 
for HPV-positive women, and every 3 years for all others, but in actuality is irregular and often 
determined by resource availability (CDC, 2018). Pap smear is most common in developed 
nations while Visual Inspection with Acetic acid (VIA) is used more often in poorly resourced 
areas (Gaffikin, 2002).  
 
2.2.1 Pap Smear 
Pap smears and colposcopies are the most common cervical cancer screening methods to 
accurately detect cellular processes of both precancerous and cancerous samples within a swab 
sample of the cervix (Markovic, 1998). Pap smear analysis requires a high degree of technical 
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and clinical knowledge to identify and swab the cervix correctly to interpret sample results for 
appropriate diagnosis. Not only is the equipment to analyze the sample expensive and laboratory 
access required for proper and effective analysis, but these procedures have a high number of 
false positives. Moreover, individual patients have indicated that Pap smears and colposcopy are 
invasive, painful, and costly, requiring regular screening every 2-3 years (Markovic, 1998).  
 
2.2.2 Visual Inspection with Acetic Acid (VIA) 
Visual Inspection with Acetic Acid (VIA) of the cervix is an inexpensive screening method used 
primarily in poorly resourced areas (Gaffikin, 2002). This screening test is performed by trained 
health workers and nurses in women’s health clinics as well as mobile screening camps in 
low-income areas. The test is invasive and can cause some discomfort similar to the Pap smear 
method because of the insertion of a self-retaining vaginal speculum. After insertion, acetic acid 
is applied to the cervix and observed for a reaction between the suspected lesion and the acetic 
acid indicated by a color change (Gaffikin, 2002). Similar to limitations of other screening 
procedures, VIA requires a high degree of technical knowledge to properly administer the 
screening, must be done in a clinical environment, and is highly invasive. If the test is not 
administered properly, bubbles may form, resulting in false positives (​Mandelblatt​, 2002).  
 
The limitations of these current technologies highlight the need for a cost-effective medical 
screening procedure that enables women in low resource settings, without access to advanced 
medical care, to accurately test for cervical cancer. Furthermore, the results of the screening 
should be easily understood by individuals with little to no technical medical background.  
 
2.3 Vaginal Microbiome 
One of the newest avenues of cancer detection research involves microbiota, which are the 
microbial communities present in certain areas of the body. These include the gastrointestinal 
tract, oral cavity, and the cervicovaginal regions. This class of organisms was chosen as a target 
for our prototype because current literature indicates that ​dysbiosis, a microbial imbalance, has 
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been linked to many diseased states, from irritable bowel syndrome to many types of cancers, 
including cervical cancer (Kriss et. al., 2018). 
There are many factors that influence the composition of the vaginal microbiome. These can 
include hygiene, lifestyle factors (i.e. sexual health, contraceptives, etc.), pregnancy, and 
menopause. The composition can change several times throughout a single individual’s lifetime. 
The bacteria present in the vaginal microbiome can be classified in one of five ways, referred to 
as Community State Types (CSTs). Each females’ vagina can be classified as CST I-V, with 
dominant bacteria in each category. The most common CSTs are III and IV, and an individual 
can transition from CST III to CST IV during their lifetime, and transitions between any two 
community state types are common (Gupta, et. al, 2019).  
Of particular interest to our team is the prevalence of vaginal dysbiosis in Sub-Saharan Africa 
(van de Wijgert and Jespers, 2017). ​A definitive causal link has been established between vaginal 
dysbiosis and cervical cancer from oncogenic HPV acquisition to cervicovaginal precancerous 
development, meaning that detection by this manner has the capability of detecting early-stage 
cervical cancer (Brusselaers, 2019) 
 
2.3.1 Fusobacteria  
Fusobacteria strains have been detected in pathogenic dysbiosis of microbiomes such as the 
colon, oral mucosa, and gut (Han, 2015). Recent work has also correlated its presence to cervical 
cancer pathology. Vaginal dysbiosis is often observed in correlation with a change in the ratio of 
healthy to pathological microorganisms, including an increase in the amount of fusobacteria. 
This dysbiosis, caused by infection or other pathology, can increase a patient’s risk to develop 
more serious conditions such as cervical cancer (Gupta et al, 2019).  
Studies have shown that ​Fusobacterium nucleatum ​is upregulated in correlation with cervical 
cancer, finding that it constitutes approximately 17% of the cervical microbiome in this disease 
state (​Audirac-Chalifour et al., 2016​). ​F. nucleatum​ is an obligate anaerobe, meaning that it can 
only grow in conditions where oxygen is absent. This is the bacteria that we are targeting with 
our research and experiments because it provides the most conclusive link to cervical cancer in 
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patients diagnosed with the disease, and is not present in high levels in the healthy microbiome.  
 
2.4 Quantification Methods 
Sensitivity testing is required in order to determine the accuracy of a screening procedure. This 
testing measures how often a test correctly generates a positive result when the targeted 
condition is present. This is known as the true positive rate (King and Mody, 2010). Producing a 
true positive result is essential for an accurate screening procedure.  
 
The National Institute of Health (NIH) launched the human microbiome project in 2008 to better 
understand microbial microenvironments in specific areas of the human body and how they 
contribute to human health and disease (Gevers, 2012). The vaginal microbiome was explored to 
gain insight into the baseline state of a healthy vaginal microbiome. Some studies also indicated 
that in women affected by cervical cancer, the composition of fusobacteria in the vaginal 
microbiome is 17% (Audirac-Chalifour et al., 2016). The composition of cervical and vaginal 
flora specimens has been proven to be comparable, therefore the vaginal microbiome can be 
representative of the cervical microbiome (Smith et. al., 2014).  
 
2.4.1 Colony Forming Units (CFU) 
When performing a quantitative test, there are several available methods for establishing a 
baseline. The selection of the proper method depends on the degree of precision desired. One of 
the easiest and most common quantification methods is counting colony-forming units (CFUs). 
This method is regarded as the gold standard for determining bacterial cell number (Hazan et al, 
2012). Utilizing this method is beneficial because only viable bacterial colonies are counted, 
excluding any dead bacteria and debris (Hazan et. al., 2012). The most significant disadvantage 
of this method is that clumps of bacteria cells can be miscounted as single colonies. While no 
specialized equipment is required for counting CFUs, there are several limitations to this method, 
including an extended incubation time of several days in order to obtain observable colonies.  
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2.4.2 Microscopy 
Compound microscopy is another method commonly utilized in bacterial quantification. 
Hemocytometers are used in conjunction with the microscope in order to determine absolute cell 
count. Using this method can be difficult because it requires the ability to differentiate between 
bacterial cells and debris, as well as being able to clearly identify clumps of bacteria (Hazan et. 
al., 2012). This method requires a specialized microscope and a hemocytometer plate, but results 
can be obtained in a shorter amount of time than CFU counting because cells can be counted 
without incubating first.  
 
2.4.3 qPCR 
Quantitative Polymerase Chain Reaction (qPCR) or Real-Time PCR is a method commonly used 
to quantify the abundance of particular microbial DNA. Analysis via qPCR combines traditional 
end-point detection PCR with detection by fluorescent expression technologies to record 
amplification in “real time” (Smith et. al., 2009). This method also provides wide sequence 
coverage, as it can specifically target particular taxonomic or functional markers from bacterial 
domain down to specific bacterial strains. The results from this method can be obtained in 
approximately 1.5 hours, but post-analysis can be difficult and time-consuming, particularly in 
developing an absolute standard curve. The standard curve development itself requires initial 
quantification by one of the aforementioned methods for qPCR verification. 
 
The table below summarizes the benefits and limitations of each of the accessible microbial 
quantification methods. 
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Table 1. Methods of Bacterial Quantification 
Quantification 
Method 
Benefits Limitations 
Colony-forming 
units (CFUs) 
● Easy to conduct 
● Counts only live cells 
● Range of detection unlimited 
● Time-consuming 
● Susceptible to 
contamination 
Compound 
Microscopy 
● Range of detection unlimited 
● Quick results  
● Relies on the ability of 
viewer to count bacterial 
colonies, large potential for 
human error 
qPCR ● Counts bacterial DNA from live, 
dead or injured cells 
● Can specifically target a particular 
bacterial strain  
● Quantification of up to 96 samples 
at once 
● Fairly quick results (hours) 
● Tedious experimental 
procedure may lead to 
errors 
● Post-analysis with standard 
curves is complicated 
 
 
2.5 Team and Project Management 
The project team is composed of three Bioengineering (BIOE) majors in conjunction with five 
Santa Clara University (SCU) faculty members, two Public Health science majors from the 
Engineering World Health (EWH) partnership, and Hiram Lozano from Anaerobe Systems. The 
faculty advisors are Dr. Prashanth Asuri, Dr. Michele Parker, Dr. Craig Stephens, Dr. Emily 
Park, and Dr. Elizabeth Dahlhoff. Dr. Prashanth Asuri has served as a Bioengineering advisor. 
Dr. Michele Parker has served as a Public Health advisor and a mentor to the Engineering World 
Health sector of the project. Dr. Craig Stephens has served as an expert in microbiology and 
advised the students on both microbiological techniques and characteristics of bacteria. He also 
provided the students with lab space and supplies. Dr. Park has served as an advisor for 
designing qPCR experiments. Dr. Dahlhoff provided lab space, materials, and expertise in 
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running a qPCR experiment. Lauren Cherrey and William Nelson acted as public health student 
partners for the project, advising the BIOE team about relevant ethical and cultural issues.  
This project originally stemmed from the work of a 2017-18 senior design group and subsequent 
iteration during the 2018-19 school year. Within the BIOE student team, all experimental design, 
presentations, intra-team communication, and lab work were completed together. In addition to 
baseline roles, individual team members had responsibilities of their own. Juliana Trujillo 
managed supply orders and was the point of contact with the School of Engineering, Lauren 
Serfas organized meetings and was the primary point of contact with advisors, and Kira Palazzo 
was the lead point of contact with Anaerobe Systems, managing updates and supply shipments 
from the company to SCU.  
 
2.5.1 Budget 
The funds provided for experimentation and development of our senior design project were 
requested from the Santa Clara University Undergraduate Programs. The awarded funding is 
summarized in​ Table A​ found in Appendix A. Additionally, a detailed outline of the 
expenditures of the project totaling $1,431.32 can be found in​ Table B​ in Appendix A.  
 
2.5.2 Timeline  
Reference Appendix A, ​Table C​ for an overview of completed action items for the CERVIS 
project for the 2019-20 school year.  
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CHAPTER 3: CERVIS PROTOTYPE PARAMETERS 
We chose three initial parameters to test conditions for feasibility: incubation time, incubation 
temperature, and aerobic exposure prior to insertion into the CERVIS media. We chose these 
parameters as the most pressing questions to assess feasibility given the limits of conditions in 
Uganda. 
 
3.1 Incubation Time 
In rural areas of Uganda, access to clinical settings may be limited. For this reason, it is 
important to minimize clinical wait times for the CERVIS screening procedure. Once the 
screening has been performed, results are not immediately available because of the necessity to 
culture the CERVIS tubes in an incubator. The purpose of the incubation time parameter test is 
to determine the minimum amount of time necessary for a true positive to be produced. This 
would be necessary for the deployment of the procedure in Uganda because it would allow for 
identifiable wait times, minimizing patient anxiety, and increasing ease of processing for 
healthcare personnel.  
 
3.1.1 Methods 
In preparation to grow fusobacteria, the anaerobic chamber was turned on and allowed to purge 
for 24 hours to remove oxygen and establish an anaerobic environment. 
 
Entering the Anaerobic Chamber 
Fusobacteria plates, which had been cultured for 96 hours, were removed and photographed. 
After the plates had been properly documented, viable colonies were removed from plates using 
sterile inoculating loops and placed into a 9 mL dilution blank. The dilution blank was then 
resealed and vortexed at speed 7 for ten seconds. Once this was completed, 1 mL of the solution 
was withdrawn from the tube and added to another 9 mL dilution tube to create a tenfold 
dilution. Once this was completed, the dilution tube was sealed and then vortexed on 7 speed for 
10 seconds to distribute the bacteria through the solution. Following the vortex, 20 µL was added 
to a sterile swab of the bacteria-containing solution; 20 µL was the amount determined to be the 
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maximum volume retained on the chosen swabs. This swab was then inserted into the media and 
sealed. The CERVIS tube was then placed into the passbox, sealed from the inside, and the team 
member exited the chamber.  
 
Outside of the Chamber 
Once removed from the chamber, the CERVIS tube was incubated at 37 ℃ and documented at 0, 
24, 48, and 72 hours.  
 
3.1.2 Preliminary Results  
According to qualitative analysis, a color change did not occur in the media at all until 48 hours, 
with a more substantial color change occurring at 72 hours. However, these results do not 
provide conclusive evidence for the exact point at which a true positive can be observed, so 
further tests would be necessary to confirm this.  
 
Incubation Time 
0 hrs 24 hrs 48 hrs 72 hrs 
    
Figure 1: Incubation Time Parameter Results 
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3.2 Incubation Temperature  
In rural villages in Uganda, access to an incubator may be severely limited, so we wanted to 
explore alternative incubation temperatures that could result in a true positive result without the 
use of a traditional incubator.  
 
3.2.1 Methods 
Within the Anaerobic Chamber 
See section 3.1.1 for details on placing fusobacteria into CERVIS media tubes.  
 
Outside of the Anaerobic Chamber 
The four CERVIS tubes designated for temperature parameter testing were placed in various 
temperatures in order to determine if bacterial growth was possible. One tube was designated to 
be at room temperature, 25 ℃, one was placed in a 37 ℃ incubator, one in a 30 ℃ incubator, 
and one in an outdoor area that would experience temperature fluctuations throughout the day. 
The tube placed outside was in a shaded area so that direct sunlight would not be a confounding 
variable. Each tube was documented after 72 and 98 hours, though the outdoor tube was only 
documented at 72 hours.  
 
3.2.2 Preliminary Results  
Without access to an incubator, it is likely that access to this procedure would be severely 
limited. According to preliminary testing, bacterial growth occurs only at 37 ℃.  
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 Temperature 
 Varying  25 ℃  37 ℃  30 ℃  
72 hours 
    
98 hours Not pictured 
   
Figure 2: Temperature Parameter Testing Results (72 and 98 hours) 
 
3.3 Aerobic Exposure 
During sample collection, it is likely that the vaginal swab would be exposed to air for at least 
several seconds to several minutes following collection by the patient. For this reason, tests were 
conducted to determine the maximum time for aerobic exposure that would allow the procedure 
to maintain viability. That is, the test was necessary to determine if exposure to air would still 
allow for a true positive result of the CERVIS procedure. A true positive can be obtained only if 
fusobacteria growth occurs, and this test would confirm the degree to which exposure of this 
anaerobic bacteria to air would inhibit growth. 
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3.3.1 Methods 
Within the Anaerobic Chamber 
Once it had been confirmed that the chamber was anaerobic, the team opened the incubator and 
took pictures of each plate. Fusobacteria that was designated for aerobic exposure testing was 
cultured. The plates were assessed for viable colony growth and set aside. Approximately 30 
viable fusobacteria colonies from the plates were ‘picked’ via a sterile 1 μL inoculating loop and 
placed into a tube containing 5 mL of dilution solution The inoculating loop was shaken 
vigorously to release the colonies into the dilution solution and the tube was sealed with the cap. 
The tube was then vortexed at speed setting seven for ten seconds to ensure even distribution of 
fusobacteria throughout the solution.  
 
Next, each swab was prepared to be inserted into the media. To do this, we vortexed the tube 
containing the bacteria for ten seconds, then removed the cap and removed 20 μL of the 
bacteria-containing solution. This was pipetted onto a swab, turning the swab as the solution was 
released to coat it in solution. Following this, the swab was then plunged into the CERVIS media 
and sealed with the cap.  
 
The twelve swabs were designated for aerobic exposure testing. The procedure of vortexing the 
bacteria-containing solution and adding it to the swab was repeated for each swab, after which 
the swab was placed in the tube rack with the tip of the swab facing upwards. Prior to exiting the 
chamber the tube rack with swabs was placed in the passbox and was sealed from the inside.  
 
Outside of the Anaerobic Chamber 
Before opening the passbox, we collected a timer and twelve new CERVIS media tubes, along 
with a tube rack to stand those in. We labeled duplicate tubes for six aerobic exposure times--15, 
30, 45, 60, 120, and 300 seconds--for a total of twelve tubes. Next, while one person was ready 
to start a timer, the other got ready to open the passbox. When the passbox was opened, the timer 
was started and watched until it was time to insert the swab into the media. Just before a time 
point was reached, both team members opened the corresponding CERVIS media tubes, selected 
 
24 
the swabs without touching the tip, carefully pushed the swabs into the media tip down, and 
resealed the tubes. This process was repeated for each time point listed above. Once all tubes 
contained swabs, they were placed into the 37 ℃ incubator and checked at 72 and 98 hours, 
capturing images each time.  
  
3.3.2 Preliminary Results  
After 72 hours, little to no distinct growth had been observed in all of the tubes. After 98 hours, 
growth was observed in all time points except for 300 seconds, but there were large 
inconsistencies between duplicates at 30, 60, and 120 seconds (see ​Figure 3​). These 
inconsistencies could be explained by the variability common in bacterial suspensions such as 
the one used for parameter testing. There is a possibility that the tubes that showed no growth 
had not received any or received very little fusobacteria in 20 µL of the bacterial suspension that 
was pipetted onto the swab. 
 
Exposure Time 
15 sec 30 sec 45 sec 60 sec 120 sec 300 sec 
      
Figure 3: Aerobic Exposure Parameter Testing (98 hours) 
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CHAPTER 4: DETERMINING SENSITIVITY OF THE CERVIS MEDIA 
The overall goal of team CERVIS this year was to determine the feasibility of last year’s 
prototype. In order to do that, one of the subgoals was to assess the sensitivity of the CERVIS 
media to ensure it could detect the amount of fusobacteria expected in the vaginal microbiome of 
a woman with cervical cancer.  
 
4.1 Objectives  
As previously mentioned, 17% of the vaginal microbiome is composed of fusobacteria. Based on 
our assumptions that a vaginal swab is representative of the vaginal microbiome for the 
sensitivity testing, we can conclude that approximately 17% of a vaginal swab is composed of 
fusobacteria for women with cervical cancer. Knowing the approximate amount of fusobacteria 
that would likely be in the vaginal swab of a woman with cervical cancer allows for a target 
percentage of how sensitive the CERVIS media needs to be in order for team CERVIS to 
consider last year’s prototype feasible.  
 
It is necessary to generate a percentage that corresponds to the sensitivity of the CERVIS media 
to compare to our target percentage of 17%. This percentage can be calculated by dividing the 
amount of fusobacteria necessary to initiate a color change in the CERVIS media by the total 
bacteria present in a vaginal swab. It has been found that total bacteria in a microbiome does not 
change depending on disease states, so the number of total bacteria that is found in the vaginal 
microbiome of a woman with or without cervical cancer should be approximately equal (Vickery 
and Ramakrishnan, 2017).  
 
Therefore, to evaluate the sensitivity of the CERVIS media, we had to determine:  
1) How much initial fusobacteria is necessary to add to the CERVIS media for a color 
change to occur (Section 4.5.1) 
2) How much total bacteria is present on a vaginal swab (Section 4.5.2) 
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4.2 General qPCR Procedure 
In order to quantify the amounts of fusobacteria and total bacteria present in the sample, we used 
quantitative Polymerase Chain Reaction, or qPCR (see description of this quantitative method in 
Section 2.4.3). The following section describes the general procedure for preparing and 
performing qPCR, which are preliminary steps necessary before running our desired 
experiments.  
 
The qPCR procedure can be broken down into three primary steps: 
1) Preparing dilutions of the bacterial DNA 
2) Creating the Universal and Fusobacteria Master Mix and NPC 
3) Combining the DNA dilutions and Master Mix on a qPCR plate 
 
Further details can be found in ​Appendix B, Section 1​. 
 
4.2.1 Preparing Fusobacteria and Primers for qPCR 
Primers are one of most, if not the most important, critical component of any PCR because they 
control the specificity and sensitivity of the analysis (Bustin, 2017). We needed to find 
“universal” primers for eubacteria, all bacteria. The universal primers used in our experiments 
were taken from a study that had previously sequenced the vaginal microbiome (Mao et al., 
2012). We found species-specific primers for ​Fusobacterium nucleatum​ as it was the species 
associated with cervical cancer pathology (Castellarin, et.al. 2012). The sequences of these 
primers are located in ​Table G​ in ​Appendix A​. 
 
Preparation of our experiments entailed growing fusobacteria in an anaerobic hood and isolating 
DNA for the qPCR procedure. In addition, primers had to be prepared from a lyophilized state 
prior to qPCR testing. The detailed methods used to perform this are described in ​Appendix B, 
Section 2​.  
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4.3 Testing Primers  
Before we could begin quantifying fusobacteria in the CERVIS media or total bacteria on a 
vaginal swab, we first had to ensure our qPCR procedure was working appropriately and our 
reaction components were performing as expected. We began by verifying that our Universal and 
Fusobacteria primers were working properly. To test the universal primers, we first ran a qPCR 
experiment with Fusobacteria and ​E. coli​. We expected both of these bacterias to produce 
amplification if they were indeed universal and our procedure was appropriate. We also ran a 
qPCR experiment using Fusobacteria and ​E. coli​ with the ​Fusobacterium nucleatum​ primers. In 
this situation, we expected the fusobacteria to produce amplification while the ​E. coli​ would not.  
 
4.3.1 Methods  
In testing the primers, we followed General qPCR Procedure as described in Appendix B, 
Section 1. We performed two ten-fold dilutions of the ​E. coli​ DNA (147 μg/mL) and fusobacteria 
DNA (2.58μg/mL) and used the 10​1​ and 10​3​  dilutions when pipetting them onto the qPCR 
plates. In preparing our Fusobacteria and UMM we calculated for 12 reactions (10 necessary + 2 
additional). See ​Table H ​and ​Figure A​ in ​Appendix A​ for the total volumes and qPCR plate 
setup.  
4.3.2 Results 
 
Figure 4: Amplification Plot for Testing Primers 
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The amplification for both the fusobacteria and universal primers is shown in ​Figure 4​. The 
x-axis is the cycle number of the qPCR machine, and the y-axis is the change in the amount of 
DNA. The lower the cycle number, the greater the amount of DNA initially present in the 
sample.  In order for there to be considered amplification, the curve must rise above the threshold 
level, determined by the horizontal green and orange lines. The point where those two lines cross 
is called the Cycle Threshold (or C​T ​value). In the lines within area A, we see that there is clearly 
amplification for both the universal and ​F. nucleatum​ primers. However, in area B, they are high 
C​T ​values (signifying very low initial amounts of DNA) so the results are inconclusive as to 
whether there was sufficient amplification or not.  
 
The following figure (​Figure 5​) shows amplification in another way that is easier to assess 
whether the primers were performing as expected.  
 
 
     ​Figure 5: Amplification Results for Testing Primers  
 
The box in blue shows the controls for the experiment (water instead of any DNA and NPC 
instead of the UMM or FMM). There should be no amplification for these eight reaction wells 
(all purple circles). The red circles signify amplification, therefore we recognize that our controls 
were not working as expected. However, looking at the amplification plot, those curves fall in 
Area B, so the data was on the borderline of being considered “amplified” or not. We recognized 
this inconsistency, but since these were preliminary experiments, we continued to move forward 
recognizing that this data was likely due to contamination from our inexperience of running these 
experiments.  
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Returning to ​Figure 5​, the top row is bacteria with the UMM (with the Universal primers), and 
the bottom row is with the FMM (with ​F. nucleatum​ primers). As mentioned previously, we 
expected there to be amplification with both the ​E.coli​ and ​F. nucleatum​ (which we see with the 
red circles) with the UMM (the top row), but there was only amplification with ​F. nucleatum 
with  FMM (the bottom row). With the ​E. coli​ and FMM, we got results that were inconsistent 
with our hypothesis, as it showed some amplification with one of ​E. coli​ concentrations. Once 
again, because we saw that the FMM was amplifying ​F. nucleatum​ (which we were more 
focused on), we took note of this inconsistency and continued to proceed forward with the rest of 
the qPCR experiments.  
4.4 Generating Absolute Standard Curves 
Once we felt comfortable with the qPCR procedure and had ensured that our Universal primers 
were amplifying different types of bacteria (​E. coli​ and ​F. nucleatum​) and our fusobacteria 
primers were amplifying ​F. nucleatum​, we then proceeded with the next step of our preliminary 
sensitivity testing which was generating universal and fusobacteria absolute standard curves.  
 
An absolute standard curve is generated from a ​known​ amount of DNA, so it can be used as a 
reference for determining an ​unknown​ amount of DNA in a sample. This was important so that 
we could determine the unknown amounts of initial fusobacteria in the CERVIS media and total 
bacteria that were present in a vaginal swab.  
 
We determined our known amount of fusobacteria present in our initial dilution using 
microscopy (See ​Appendix B, Section 3​). We then used the amount of fusobacteria DNA from 
our microscopy results and entered them into the standard curve technology programmed into the 
qPCR machine. This automatically created our Fusobacteria absolute standard curve and 
universal absolute standard curve.  
 
4.4.1 Methods 
After determining through microscopy how much fusobacteria in our initial dilution, we then 
followed the “General qPCR Procedure” as described in ​Appendix B, Section 1​. We performed 
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five, ten-fold dilutions of fusobacteria DNA (6.08 μg/ml) and used all five dilutions when 
pipetting them onto the qPCR plate. In preparing our Fusobacteria and Universal master mix we 
calculated for 13 reactions (11 necessary + 2 additional). The total volumes and qPCR can be 
found in ​Table J​ and​ Figure B​ in ​Appendix A​.  
4.4.2 Results 
 
Figure 6: Standard Curves 
 
The fusobacteria standard curve (orange) and universal standard curve (purple) are shown in 
Figure 6​. The amount of bacteria is shown on the x-axis, and a measure of amplification (C​T 
value) is shown on the y-axis (see Results section for Testing primers for a more detailed 
explanation of C​T​ value). In order for an absolute standard curve to be considered precise enough 
for determining unknown DNA amounts, the r​2​ value has to be greater than or equal to 0.999. 
Therefore, while our fusobacteria standard curve (r​2 ​= 1.000) would be precise enough, our 
universal standard curve (r​2 ​= 0.925) would not. Unfortunately, we were in the middle of 
repeating this experiment to increase our r​2 ​value when Santa Clara University closed all labs, so 
we did not get to generate standard curves that could be used for the rest of the sensitivity 
testing.  
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4.5 Sensitivity Testing Experiments 
Once appropriate standard curves were created, we could then return to the two primary 
quantities we needed to determine in order to assess whether the CERVIS media was sensitive 
enough for women with cervical cancer: 
1) How much initial fusobacteria is necessary to add to the CERVIS media for a color 
change to occur?  
2) How much total bacteria is present on a vaginal swab of a healthy woman? 
4.5.1 Determining Initial Quantity of Fusobacteria Required for Color Change 
In order to determine how much initial fusobacteria was necessary for a color change to occur in 
the CERVIS media, we first had to assess where a dramatic color change was occurring. 
Therefore, fusobacteria was grown in an anaerobic chamber for 96 hours. Approximately 50 
colonies were then placed into a dilution blank containing 9 mL of dilution solution and vortexed 
well. 1 mL of this bacteria suspension was then added to a tube containing 9 mL of dilution 
solution (1:10 dilution). Five 1:100 dilutions were then made by taking 100 μL of the bacteria 
suspension from the previous dilution and adding it to a new tube containing 9.9 mL of dilution 
solution. The contents were then vortexed well before creating the next dilution. Furthermore, in 
total there were the following dilutions: the initial dilution, 1:10​1​, 1:10​3​, 1:10​5​, 1:10​7​, and 1:10​9​.  
 
From the dilutions following the initial one, 20 μL of each were pipetted onto clean swabs and 
each placed into a tube containing the CERVIS media. The caps were then placed on each of the 
tubes and taken outside of the anaerobic hood and placed in the 37 °C incubator. The color 
change was then observed every 24 hours, and at 72 hours, it was observed that there was a 
significant color change in at least some of the CERVIS tubes. As shown in the table below, at 
72 hours, we observed that the 1:10​1​ and 1:10​3 ​dilutions had undergone significant color changes.  
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Time (hrs) 1:10​1 1:10​3 1:10​5 1:10​7 1:10​9 
24 
     
48 
    
 
72 
     
Figure 7: Bacterial Growth Based on Dilution Factor 
 
Due to time constraints, we did not get to complete the rest of this sensitivity procedure as 
planned, but we still had developed the overall procedure of how we would complete the rest of 
this experiment.  
 
Proposed Experiment 
After it had been determined where the color change was occurring within the CERVIS media 
tube, we would then take the 1:10​1​ and 1:10​3​ fusobacteria dilutions which were initially pipetted 
onto those swabs outside of the hood, and perform DNA miniprep according to Qiagen DNeasy 
Miniprep kit (cat. nos. 27104). At that point, we would then perform a qPCR reaction by adding 
the normal qPCR components (SYBR Green Master Mix, qPCR grade water) with the forward 
and reverse fusobacteria primers (see ​Appendix B, Section 1 ​for qPCR experiment methods) 
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Therefore, the qPCR machine would amplify the fusobacteria in those dilutions. By plotting the 
Ct values generated from the qPCR machine onto the fusobacteria standard curve generated 
earlier, it could then be determined how much initial fusobacteria was present in the CERVIS 
media where the color change occurred. This would serve as one of the critical numbers that 
would be needed in order to generate a percentage to compare to 17% (the percentage of 
fusobacteria present on a vaginal swab of a woman with cervical cancer).  
 
4.5.2 Determining Total Bacteria Present on a Vaginal Swab 
The second critical number that needed to be obtained was the total amount of bacteria present in 
a vaginal swab. To do this, we first needed to collect a vaginal swab.  
 
Obtaining a vaginal swab 
Three women from Santa Clara University took gloves and a sterile swab placed in a bag to the 
restroom. The swab was removed from the bag using sterilized forceps and the swab was 
inserted 1-2 inches into the vagina. After rotating the swab three times inside the vagina, it was 
quickly inserted into a dilution blank and the lid was closed. The dilution blank was further taken 
to the lab for DNA miniprep.  
 
DNA Miniprep with Tissue Sample 
The samples were vortexed for 30 seconds and then prepared according to the protocol for 
“cultured cells” in the Qiagen DNeasy Miniprep kit (cat. nos. 27104). The DNA was stored in 
the 20 ℃ freezer until ready for use in quantitative PCR (qPCR).  
 
Proposed qPCR experiment with vaginal swab 
While we did have the opportunity to obtain vaginal DNA, we did not get the opportunity to 
perform a qPCR experiment with this DNA to determine how much total bacteria was present in 
a vaginal swab. However, below is the overall procedure for how we would have done so: 
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After the vaginal DNA was obtained, it would be added to SYBR Green Master Mix, and the 
forward and reverse universal primers. This would amplify all of the DNA found in the vaginal 
DNA. After a normal qPCR test was run (see Appendix B, Section 1 for qPCR procedure), the Ct 
values given to us from the amplification plot from the qPCR machine would be plotted on the 
universal standard curve. This would further tell us how many total bacteria is on a vaginal swab, 
which is the second critical number.  
 
4.5.3 Conclusion of Sensitivity Testing 
After determining both the amount of initial fusobacteria necessary for a significant color change 
to occur in the CERVIS media and the total amount of bacteria in a vaginal swab, a percentage 
could then be generated (dividing the fusobacteria by the total bacteria). This number could then 
be compared to 17% of fusobacteria that we would expect to find in the vaginal swab of a 
woman with cervical cancer. If the percentage was approximately 17%, we could conclude that 
the CERVIS media is sensitive enough and therefore, last year’s prototype has feasible 
sensitivity.  
 
Unfortunately, because the amounts of fusobacteria and total bacteria were not able to be 
determined, we could not generate a percentage. However, we believe that this procedure would 
lead us to draw a conclusion of whether the CERVIS media has feasible sensitivity.  
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CHAPTER 5: IMPLEMENTATION MODALITIES 
5.1 qPCR as Modality 
The original purpose of qPCR experiments was to test the feasibility of the CERVIS media 
sensitivity. However, we realized that the qPCR procedure could also be used as a clinical 
modality to screen women for cervical cancer if a qPCR machine was accessible. Using the 
patient’s vaginal swab, the amount of fusobacteria, and the total amount of bacteria could be 
determined and plotted on the standard curves to assess the patient for cervical cancer pathology. 
This would allow us to generate a percentage, which we could compare to the 17% to assess 
whether the woman likely had cervical cancer or not. Therefore, qPCR in itself could be 
considered another minimally-invasive implementation modality along with the CERVIS media. 
 
5.2 Comparison of Modalities 
We identified two implementation modalities: the CERVIS Media and qPCR experiments. While 
both are potentially applicable in a clinical setting, there are several key differences between the 
two. The main points are summarized in a table ​(Table 3)​ after the following explanations. 
 
First, the CERVIS media is colorimetric and therefore qualitative, while qPCR is a purely 
quantitative test. Since the qPCR modality requires specialized equipment, it would be better 
suited for communities with pre-existing access to the technology, while the CERVIS media is 
ideal for communities without access. There is also a substantial difference between the wait 
time for the results of each modality. The CERVIS media relies on the growth of bacteria and 
thus requires three to four days for incubation, while the qPCR will determine results much more 
rapidly in only a few hours. Both modalities are potentially low enough cost for LMICs if the 
qPCR technology is already available.  
 
While the CERVIS media may be more easily implemented in LMICs, preliminary parameter 
results suggest the requirement of incubation technology and extended incubation times. These 
characteristics may pose significant barriers to clinical implementation in Uganda. A limitation 
of the qPCR modality is the requirement of specialized machinery and its accessories, which 
 
36 
could contribute to an initial high cost. The qPCR cost decreases as more tests are run, which 
could vary individual testing costs.  
 
Additionally, both modalities rely on increased concentrations of fusobacteria in the vaginal 
microbiome. Fusobacterium colonization of the vagina has also been associated with preterm 
birth and a few other uterine infections, so women with these conditions may not be able to 
utilize either procedure. Additionally, there remain some cultural limitations of deployment, such 
as lack of education surrounding sexual health and the necessity of a community-wide effort to 
empower women to care for their own health. Fortunately, we had two public health partners on 
our team that worked this year to bridge this gap of education and women’s health empowerment 
through the creation of educational brochures. Despite these constraints, we believe that CERVIS 
has promising future directions.  
 
Table 2: Summary of the Comparison of Modalities 
CERVIS Media Both qPCR 
● Qualitative test 
● Ideal for communities 
without access to 
qPCR technology  
● Results in days 
● Could be low enough 
cost for LMICs 
● Quantitative test 
● Requires highly 
specific lab 
technology 
● Results in hours 
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CHAPTER 6: SPECIFICITY TESTING 
In order for the CERVIS media to be considered functional, it needs to be specific to cervical 
cancer. This specificity testing is important because the test can be utilized for detecting a 
particular disease, rather than generally detecting a bacteria. A goal for CERVIS this year was to 
determine an additional bacterial biomarker that is associated with cervical cancer so that the 
procedure is more specific. Unfortunately, an extensive literature review has not yet revealed a 
promising candidate to increase specificity, so in this section, we will speculate on what criteria 
would make an optimal candidate.  
 
This year, CERVIS focused experiments on the sensitivity of the media to detect fusobacteria. 
Sensitivity indicates the true positive of a test, or the ability to correctly identify individuals with 
the disease. Another indicator of how accurate a test relies on specificity, the ability to correctly 
identify individuals without the disease. Highly sensitive and specific tests are the most accurate, 
so both must be considered. 
 
6.1 Selection Criteria for Bacteria 
One method of increasing specificity would be to identify a second bacteria to be analyzed 
alongside fusobacteria. Currently, there exists no conclusive data on other microbiota implicated 
in cervical cancer, but we have developed criteria that this such bacteria would fulfill. In order to 
be considered for further analysis, the bacteria must be present or capable of being detected in 
cancerous vaginal microbiomes. This is in order to enable the vaginal swab to be effective, i.e. 
able to pick up this bacteria when the test is administered. The second criterion is that it be 
absent or in significantly low quantities in a non-cancerous vaginal microbiome. This is to 
enhance the sensitivity of both qPCR and CERVIS media screening procedures, ensuring that 
only cancerous vaginal states are detected. Preliminary parameter testing suggests that incubation 
at the typical 37°C for over 72 hours is a requirement for fusobacteria, thus any bacteria that 
grow at that temperature or below and for that time or shorter is acceptable. Furthermore, 
preliminary tests for aerobic tests indicate the possibility of up to 120 seconds of aerobic 
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exposure before no growth is seen in a swab, so the bacteria selected would also need to be able 
to withstand aerobic exposure for a reasonable amount of time.  
 
In qPCR, specificity can be increased by focusing on exclusivity and inclusivity. Exclusivity 
refers to distinguishing the target strain from similar but genetically distinct non-target strains 
through highly specific primers for implementation. As mentioned in Chapter 4, primers for the 
exact species, ​Fusobacterium nucleatum​, were used to narrow the scope of detected bacteria. The 
second method for increasing PCR specificity is inclusivity, or the range of the qPCR used to 
detect a wide range of targets with defined relations such as taxonomic, immunological, and 
genetic compositions (Kralik and Ricchi, 2017). Probe-based qPCR assays may also confer an 
additional level of specificity, because of its ability to multiplex multiple targets, meaning that 
two targets are amplified at once. If a secondary or alternative bacteria were to be identified and 
associated with cervical cancer, probe-based qPCR can be used to amplify multiple targets in a 
single reaction (Thermofisher, 2020).  
 
An additional qPCR application would be to screen for HPV strains 16 and 18 strains 16 and 18 
directly due to their strong correlation to cervical cancer. HPV may be present years prior to 
cervical cancer development, while fusobacteria is more strongly correlated with later stages of 
cervical cancer. Targeting both in qPCR could be a more accurate indicator of significant and 
later stages of cancer development. 
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CHAPTER 7: CONCLUSION & FUTURE DIRECTIONS  
 
7.1 CERVIS Media Parameters  
For the three parameters—time, temperature, and aerobic exposure—we have only preliminary 
data, due to our interrupted time in the lab. However, we were able to determine suggested 
parameters for our procedure based on our results. Based on these results we found certain 
limitations and future directions. One limitation common to all of our parameter tests was limited 
lab time. Time allowing, we would have repeated all parameter experiments and would have run 
all of our tests in triplicate.  
 
7.2 Preliminary Results for Incubation Time 
We concluded that the optimal time range for incubation at 37 ℃ is between 72 and 98 hours. 
While standard incubation times for fusobacteria range from 24-48 hours, when grown in the 
CERVIS media, a significant darkening of the media was only observed within the indicated 
time range.  
 
7.2.1 Limitations  
One of the major limitations of our procedure itself is the extended period of incubation required 
to produce a true positive result. Results are not immediately available, which poses an ethical 
dilemma because it could potentially cause heightened anxiety while patients wait for results of 
the test. This may also require a waiting period for the woman to receive treatment if needed. 
This is a shorter duration than a Pap smear, which can take up to 3 weeks to see results, but a 
longer wait time than VIA, which can give results almost immediately. Same-day results are 
ideal for LMICs, as many women may not have access to a clinic in rural areas and may need to 
travel to a city to receive treatment.  
 
In order to continue to improve the procedure, it would be necessary to explore avenues to 
decrease fusobacteria growth time. If possible, there would need to be adjustments to the media 
in order to promote the growth of bacteria.  
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7.3 Preliminary Results for Incubation Temperature 
Based on preliminary data testing for incubation at room temperature, 25 ℃, standard incubation 
temperature (body temperature), 37 ℃, and the temperature of an available incubator, 30 ℃, we 
determined that 37 ℃ is the preferable incubation temperature. However, we acknowledge that 
there would need to be additional trials at temperatures between 30 ℃ and 37 ℃ as well as 
extended incubation times at lower temperatures such as room temperature to confirm this result. 
We also would have conducted testing on the effect of varying temperatures on fusobacteria 
growth. 
 
7.3.1 Limitations 
A major limitation of the observed incubation temperature preliminary findings is that if there is 
limited access to an incubator at 37 ℃, then the procedure may not be able to produce a true 
positive result. Average temperatures in Uganda are often lower than 37 ℃, which would make 
incubation at room temperature unlikely according to our current findings.  
 
7.4 Preliminary Results for Aerobic Exposure  
Based on preliminary data, we concluded that fusobacteria-containing swabs can be exposed to 
air for at least two minutes and still produce a true positive result. This is a reasonable collection 
time for a vaginal swab, which indicates that this test could be viable once ready for deployment. 
Further exploration into the time period between 120 and 300 seconds is required to establish a 
true threshold for when fusobacteria is no longer viable.  
 
7.4.1 Limitations  
Another limitation of our experimental design was inconsistency in results between duplicate 
tests. Due to the variability of the bacterial suspension, there was no way to tell how much 
bacteria was contained in the 20 μL of solution that was pipetted onto the swab. In order for 
consistent results to be obtained, the tests must be repeated to ensure that each swab has 
fusobacteria on it when placed into the media.  
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7.5 Sensitivity Results 
Time constraints prohibited us from determining whether last year’s prototype has feasible 
sensitivity to screen for cervical cancer. However, we were able to develop an absolute standard 
curve and an experimental procedure that would allow us to determine the amount of 
fusobacteria needed in the CERVIS media for a color change to occur. This amount would have 
enabled us to generate a percentage that we could compare to 17%, the amount of expected 
fusobacteria present in a vaginal swab of women with cervical cancer. With such results, we 
could then conclude whether the CERVIS media was sensitive enough to screen for cervical 
cancer.  
 
7.6 Future Directions 
Our shortened time in the lab left us with preliminary results of the CERVIS media parameters, 
but there are other elements to consider to further define field testing parameters. These include 
the effects of varying temperature, humidity, and other related environmental factors. While we 
largely focused on sensitivity, determining true negatives by increasing specificity may also play 
a part in creating a more accurate prototype and qPCR procedure. This may come in the form of 
additional precancerous or cancerous biomarkers, but there are many more to explore. In order to 
standardize the color change occurring in the CERVIS media, we believe a color gradient chart 
would be beneficial to accompany the media for deployment. Finally, an important future step in 
our project would be to find a clinical or industry partner to test both modalities with vaginal 
swab samples of women with cervical cancer. Establishing this partnership is essential to assess 
the functionality of each procedure.  
 
This year, team CERVIS designed experiments to confirm the feasibility of screening for 
cervical cancer using fusobacteria in vaginal samples for LMICs. This procedure is intended to 
be sensitive, low-cost, and minimally invasive which we believe could help increase screening in 
Uganda. We established two modalities—the colorimetric CERVIS media and qPCR—and both 
of these could have future implications. The potential low cost of qPCR creates a market for 
low-income or uninsured women in developed countries such as the United States. Furthermore, 
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fusobacteria is associated with other types of cancers such as oropharyngeal & colon cancers and 
has the potential for screening. These implications indicated that screening for this particular 
bacteria has potential beyond the scope of our project. 
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CHAPTER 8: ENGINEERING STANDARDS 
 
8.1 Realistic Constraints  
Both the qPCR and colorimetric CERVIS media assay procedures are reliant upon the detection 
of ​Fusobacterium nucleatum ​bacteria in the vagina​, ​the strain linked to cervical cancer 
(​Audirac-Chalifour et al., 2016​). However, that particular species has also been linked to preterm 
birth and intrauterine infection (Diguilio, 2012). Additionally, the presence of sialidase, a 
biochemical marker, promotes growth of fusobacterium nucleatum (Agarwal et. al., 2018). 
Furthermore, women who test positive for bacterial vaginosis are more likely to be vaginally 
colonized by ​Fusobacterium nucleatum​, which may be a cause of the preterm birth (Han et. al., 
2009). Due to these findings, it may be inferred that the upregulation of fusobacteria may occur 
in women with bacterial vaginosis or those who have just given birth preterm. Similarly, high 
levels of sialidase in addition to fusobacteria, there may be causing upregulation. These disease 
states are not indicative of cervical cancer, and therefore we must suggest that women with these 
conditions be excluded from screening by our methods. 
 
One of the significant constraints in the deployment of either procedure in Uganda and other 
LMICs is the cultural limitation. The lack of education surrounding sexual health, in particular 
cervical cancer screening as well as the necessity of a community-wide effort to empower 
women to take care of their own health. An additional cultural constraint is the reticence to seek 
pelvic examinations, so even in countries with screening in place, women may not seek treatment 
until they present with advanced disease (Sankaranarayanan et al., 1998; Juárez-Figueroa et al., 
1998; Safaeian et al., 2007). 
 
8.2 Ethics  
Ethical Justification for Project 
The primary ethical justification for our project centers on the principle of justice. The principle 
of justice states that all humans have inherent dignity in and of themselves, and as such have 
fundamental human rights. These rights include access to good healthcare that will allow them to 
maintain their health to the highest possible degree. Article 25 of the Universal Declaration of 
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Human Rights written and distributed by the United Nations states that each person “has the 
right to a standard of living adequate for the health and well-being of himself and his family, 
including….medical care and necessary social services” (United Nations, 1948). Therefore, 
anyone who does not have an equal opportunity to access medical care must be prioritized. 
Additionally, a collaboration between nations with more resources and those with less could lead 
to better inter-country relationships, establishing a global community.  
 
Our project focuses specifically on women’s health in Sub-Saharan Africa, namely Uganda. 
Women’s health is a globally significant issue but is especially relevant in this region because of 
the shortages in equipment and personnel. Our main focus, cervical cancer, is very deadly, 
especially in areas with limited access to preventative, screening, and diagnostic measures. 
Without access to these measures, the incidence of cervical cancer and the mortality rate of 
women in this region of the world will remain high.  
 
Developing a procedure that is minimally invasive, low cost, and can be self-administered has 
the potential to benefit the common good by increasing screening rates in Uganda. Limiting the 
number of highly invasive procedures such as VIA or the Pap smear will help to minimize 
unnecessary procedures and costs respectively.  
 
What Does Our Product Teach Us About the Character of an Engineer? 
According to the Biomedical Engineering Society (BMES) code of ethics, biomedical engineers 
have certain ethical responsibilities that they must adhere to when working in the field. These 
responsibilities extend to us as undergraduate researchers, especially because our procedure is 
intended to have clinical applications. These ethical responsibilities can be categorized in three 
ways: healthcare obligations, professional obligations, and research obligations.  
 
The healthcare obligations that help to elucidate the ethical focus of our project involve 
“consider[ing] the larger consequences of [our] work in regard to cost, availability, and delivery 
of healthcare” (BMES Code of Ethics). With the target population of our procedure residing in 
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Uganda, it is important to create a procedure that can be readily available, low cost, and easy to 
distribute. Working with the Santa Clara University Frugal Innovation Hub and the connections 
that we met during the Collaborate 4 Africa event, our team was able to better understand the 
needs of the women living in Uganda. The aspects of our prototype that focus on addressing the 
obligations include the low cost, easy accessibility (capability to be self-administered), and 
small, self-contained design that would allow for ease of distribution.  
 
The professional obligations associated with our project include using our “knowledge, skills, 
and abilities to enhance the safety, health, and welfare of the public” (BMES Code of Ethics). 
Using the knowledge we have gleaned as undergraduates and with the help of faculty and 
industry advisors, we have sought to create a procedure that is safe and acknowledges the needs 
of the women in rural Uganda. By conducting experiments to enhance our understanding of 
cervical cancer and the prototype created, we have worked towards enhancing the health of the 
public.  
 
Finally, the research obligations associated with our project included complying with university 
standards and documenting our research carefully. In complying with university safety 
guidelines, we completed biology/microbiology general safety training and lab-specific training, 
to ensure that our team doesn’t put our own safety or the safety of others in jeopardy. 
Additionally, we carefully documented all of our work to ensure that future iterations of the 
project are possible and any work that we performed may be easily repeatable.  
 
Ethical Challenges Regarding Safety & Risk 
The main ethical challenge regarding the safety of our procedure was the use of anaerobic 
bacteria in our experiments. Utilizing this type of pathological bacteria meant that we needed to 
make sure that no contamination occurred and that none came into contact with skin, eyes, etc. 
To combat this, we followed the safety guidelines dictated by the university as well as national 
standards, which included keeping the bacteria inside the lab. 
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8.3 Engineering Standards  
Besides ethics, our design incorporates economic, social, and health and safety engineering 
standards.  
Economic 
Due to the focus of our project primarily being determining feasibility and assessing preliminary 
results of the CERVIS media, we understand that the exact cost is not within the scope of our 
project. Because our target population of women resides in Uganda, we would want the cost of 
our procedure to be comparable to VIA, which would mean between about $5-20 (Quentin et. al, 
2011). Our second modality, the qPCR procedure, relies on a SYBR Green-based assay. We 
chose this for its economical feasibility while doing a few preliminary tests on single targets. 
However, if this procedure were to be scaled up, probe-based qPCR assays would be the better 
option to ensure specificity in addition to sensitivity (Thermofisher, 2020). 
 
Social and Cultural Impact 
The primary goal of our project design is to have a significant social and cultural impact. 
Because of Uganda’s extremely low rate of cervical cancer screening, it follows that cervical 
cancer is the leading cause of cancer-related deaths in Ugandan women. One reason for low 
screening is a lack of education surrounding sexual health and the necessity of a 
community-wide effort to empower women to take care of their own health. Our two public 
health partners have been working to bridge this gap of education and women’s health 
empowerment through the design of an educational brochure.  
 
Some factors that inhibit women’s engagement in cervical cancer screening have been identified 
as fear of the screening procedure, fear of the outcome, residing in a remote or rural area, limited 
resources/health infrastructure, and limited access to screening care (Black, 2019). These point to 
immediate ethical concerns of interpersonal communication of women’s health conditions and 
strategies for treatment as well as considerations for prototype function; therefore, we intend for 
this prototype to be deployed in a healthcare clinic. 
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Health and Safety 
The most important components of our project are health and safety. Our goal is to improve the 
health of women by enabling them to screen for cervical cancer, the fourth most common cancer 
in women around the world. However, the majority of the deaths that occur due to cervical 
cancer are in LMICs. Many of these deaths could be prevented by screening and early diagnosis. 
The main objective of the CERVIS procedure is to provide a way to increase screening through 
the development of a sensitive, low-cost, minimally invasive screening procedure that requires 
minimal healthcare expertise to administer.   
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APPENDIX A: Tables & Figures 
 
Table A: Funding Received 
Source of Funding Amount Received 
SCU School of Engineering $1500 
Xilinx Grant $500 
Total Received  $2000 
 
Table B: CERVIS Expenditures 
Product 
Category 
Product Name Product 
Number 
Unit Cost Total Cost 
Lab 
Consumables 
Puritan 3306-U Standard 
PurFlock Ultra Flocked Tip 
Applicators with Polystyrene 
Shaft 3306-U 
$13.65 $19.00 
Anaerobe Indicator Test for 
microbiology 59886-1PAK-F 
$76.12 $82.97 
Nitrogen Gas Tank 
-- 
$193.00 $460.00 
0.1-10 microliter pipette tips 69504 $91.01 $103.68 
Cell Culture 
Consumables 
Water, Sterile. WFI Quality., 
Poly Bottle, 500 mL 
4.86505.0500 
$17.91 $39.23 
iTaq™ Universal SYBR® 
Green Supermix, 200 x 20 µL 
rxns, 2 mL (2 x 1 mL) 
1725120 $139.00 $173.31 
Tissue kits DNeasy Blood & Tissue Kit 
(50) 
69504 $171.00 $231.23 
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Fusobacteria-
related items 
Fusobacterium nucleatum 
subsp. nucleatum Knorr 
 
25586 
$61.20 $292.65 
Fuso and universal primers 19084632 - $29.25 
Total Expenditures: -  $1,431.32 
 
Table C: 2019-2020 Academic Timeline for CERVIS  
 Fall Quarter Winter Quarter Spring Quarter 
Week 1 ● Partnership formed 
between BIOE 
students and EWH 
students 
● Additional materials and 
primers ordered  
● Lab trained to Dr. 
Whittal’s lab (for qPCR 
access) 
● Wrote overview for 
sensitivity protocol 
● Brainstorming session 
for new direction of 
CERVIS after all 
future lab work is 
canceled 
Week 2 ● First meeting with 
engineering team 
members and advisor 
● Plate Vaginal bacteria  
● Performed CFU 
experiment with vaginal 
samples 
● Met with Dr. Park and 
agreed to move forward 
with qPCR 
● Additional Literature 
Review on Vaginal 
microbiome 
● Discuss future 
direction with project 
advisors  
Week 3 ● Define goals and 
parameters for 
CERVIS  
● Literature research on 
existing diagnostic 
tests 
● Initial meeting with 
Dr. Stephens  
● Order materials for 
qPCR 
● Meeting with Dr. 
Dahlhoff to be trained on 
running a qPCR 
experiment in the lab 
● Meeting with Dr. Park 
on how to create a 
Standard Curve on the 
● Meet with advisors to 
discuss “the story” of 
our final Senior 
Design Presentation 
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qPCR machine 
● Develop overview of 
experimental procedure 
for sensitivity testing 
with qPCR  
Week 4 ● Initial meeting with 
Dr. Parker, Will, and 
Lauren 
● Brainstorming Session 
on constraints and key 
questions for CERVIS  
● Trained by Dr. Ruscetti 
in the Anaerobic hood  
● Presentation to Dr. 
Parker on first half of 
Senior Design 
Presentation 
Week 5 ● Meet with Clarie 
Hultquist from last 
year’s CERVIS team 
to discuss 
recommendations on 
our future direction 
● Literature review on 
biomarkers in the 
blood, urine, and 
menstrual blood 
● Senior Design 
Funding Proposal 
submitted to School of 
Engineering 
● Took vaginal samples 
and purified them using 
the DNeasy kit  
● Determined 
concentration of vaginal 
samples using Qubit 
● Met with Dr. Park and 
Dr. Dahlhoff to discuss 
qPCR experimental 
design and setup 
● Ran qPCR on E. coli 
with Universal primer 
● Updated presentation 
to Dr. Parker  
Week 6 ● Research other 
possible bacteria to 
increase specificity of 
CERVIS media 
● Plated ​Fusobacteria 
● Ran qPCR experiment 
with Universal and 
Fusobacteria primers on 
vaginal bacteria  
● Determine color change 
of CERVIS media after 
adding in ​Fusobacteria 
● CFU experiment with 
Fusobacteria 
● Presentation to Dr. 
Parker and Dr. Asuri 
● Submit RD of chapters 
3-5 of thesis  
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Week 7 ● Research other 
possible bacteria to 
increase specificity of 
CERVIS media 
● qPCR experiments with 
E. coli ​and ​Fusobacteria 
and Universal and 
Fusobacteria primers 
● Run through 
presentation with 
technical and 
non-technical 
individuals 
Week 8 ● Safety trained in Dr. 
Stephens lab 
● Plate additional 
Fusobacteria​ in 
anaerobic hood 
● qPCR experiments with 
E. coli ​and ​Fusobacteria 
and Universal and 
Fusobacteria primers 
● Submit recording of 
Senior Design 
Presentation 
Week 9 ● Presentation for 
Collaborate 4 Africa  
● Met with Hiram at 
Anaerobic Systems  
● Replate ​Fusobacteria 
● CFU experiment with 
Fusobacteria 
● Meeting with Dr. 
Stephens on using a 
high-powered 
microscope for counting 
bacteria  
● qPCR experiments with 
E. coli, Fusobacteria​ and 
vaginal bacteria using 
Universal and 
Fusobacteria primers 
● Parameter testing with 
CERVIS media 
(temperature, aerobic 
conditions) 
● Hemocytometer 
counting 
● Create Universal and 
Fusobacteria standard 
curves with fusobacteria  
● IEEE Conference 
Presentation 
● Senior Design 
Presentation 
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Week 
10 
● Order materials from 
Anaerobe Systems  
● Practice streaking 
plates with E. coli 
● Anaerobicity testing 
with ​E. coli​ in an 
anaerobic pouch, 
anaerobic jar, and 
aerobic conditions  
● Create Universal and 
Fusobacteria standard 
curves with fusobacteria  
● Classes moved to online 
platform; labs closed 
● Final Thesis 
Submission 
 
Table D: Universal Master Mix Experimental Setup qPCR 
Reagents Volume/reaction 
SYBR Green Master Mix 5 μL 
Universal Forward Primer 0.2 μL 
Universal Reverse Primer 0.2 μL 
PCR grade water 2.6 μL  
 
Table E: Fusobacteria Master Mix Experimental Setup qPCR 
Reagents Volume/reaction 
SYBR Green Master Mix 5 μL 
Fusobacteria Forward Primer 0.2 μL 
Fusobacteria Reverse Primer 0.2 μL 
PCR grade water 2.6 μL  
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Table F: No Primer Control (NPC) Experimental Setup qPCR 
Reagents Volume/reaction 
SYBR Green Master Mix 5 μL 
PCR grade water 3 μL  
 
Table G: Primer Sequences Used in qPCR Experiments  
Primer Primer sequence 
Fusobacterium 
nucleatum  
F:  5’- CAACCATTACTTTAACTCTACCATGTTCA-3’ 
R:  5’-GTTGACTTTACAGAAGGAGATTATGTAAAAATC-3’ 
Universal Primer  F:  5' CCTACGGGNGGCWGCAG 3'  
R:  5' GACTACHVGGGTATCTA ATCC 3' 
 
Table H: UMM and FMM Total Volumes (Testing Primers) 
Reagents Volume/10 μL Number of reactions Total Volume 
SYBR Green Master Mix 5 μL 12 60 μL  
Forward Primer 0.2 μL 12 2.4 μL  
Reverse Primer 0.2 μL 12 2.4 μL  
PCR grade water 2.6 μL  12 31.2 μL  
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Figure A: qPCR Plate Setup for Testing Primers 
 
Table J: UMM and FMM Total Volumes (Absolute Standard Curve) 
Reagents Volume/10 μL Number of reactions Total Volume 
SYBR Green Master Mix 5 μL 13 65 μL  
Forward Primer 0.2 μL 13 2.6 μL  
Reverse Primer 0.2 μL 13 2.6 μL  
PCR grade water 2.6 μL  13 33.8 μL  
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Figure B: qPCR Plate Setup for Generating an Absolute Standard Curve 
 
 
Figure C: Amplification Plot for Generating an Absolute Standard Curve  
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APPENDIX B: Supplemental Information 
Section 1: General qPCR Procedure 
1. Preparing dilutions of the bacterial DNA 
The bacterial DNA (either fusobacteria or ​E. coli​) was removed from the -20 ℃ freezer, placed 
on ice, and given time to defrost. Serial dilutions of the DNA were created in nuclease-free 
tubes. These tubes were labeled according to their dilution, which was dependent upon the 
particular experiment and type of bacterial DNA. PCR grade water was the diluent and the total 
amount of volume for each dilution was 20 μL. Each dilution was mixed by agitation of the tube 
(“finger flicking”) and centrifuged for five seconds.  
 
2. Creating the Universal and Fusobacteria Master Mix and NPC 
The forward and reverse universal and fusobacteria primers along with the SYBR Green Master 
Mix were removed from the -20 ℃ freezer, placed on ice, and given time to defrost. Depending 
on the number of reactions that were being performed for the given experiment, a different 
amount of the primers, PCR grade water, and SYBR Green Master Mix were combined to form 
the Universal Master Mix (UMM), Fusobacteria Master Mix (FMM), and No Primer Control 
(NPC). See ​Table D-F​ in Appendix A for the amount of each component added per 10 μL 
reaction.  
 
The given experiment determined how many reactions were being performed (i.e., how many 
wells were going to be used on the qPCR plate). Once the total volume for each of the reagents 
was determined (obtained by multiplying volume/reaction with the total number of reactions), all 
components for the UMM, FMM, or NPC were combined separately in a labeled 1.5 mL 
centrifuge tube. The components were then agitated  (“finger flicked”) and centrifuged for three 
seconds.  
 
3. Combining the DNA dilutions and Master Mix on a qPCR plate 
To set up the qPCR plate, a 0.1 mL 96-well plate was placed on a qPCR specific metal ice block. 
The UMM, FMM, NPC, and bacterial DNA dilutions were all placed on ice. Eight μL of either 
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NPC (for the control), UMM, or FMM was pipetted into each reaction well according to the 
particular experiment. Bacterial DNA or water for control (2 μL) was then added to each reaction 
well. Layouts of these experiments can be found in ​Figures A & B​ in Appendix A. 
 
Microplate well caps were then sealed onto all the filled wells of the qPCR plate. Once sealed, 
the qPCR plate was then centrifuged in a salad spinner and spun for 1 minute. The plate was 
examined for bubbles and centrifuged again until no bubbles were observed in the plate. The 
plate was loaded into the qPCR machine and began running by pressing “Run Program.” The 
plate ran for about 1.5 hours and was subjected to further analysis once completed. 
 
Section 2: Preparing Fusobacteria and Primers for qPCR 
Preparations for Growing Fusobacteria 
Experiments with fusobacteria were conducted in the anaerobic hood. Before plating, a white to 
pink anaerobic indicator was opened inside of the chamber to establish that the environment was 
indeed anaerobic. Using a 1 mL needle syringe, dilution media was withdrawn and added to the 
fusobacteria pellet to rehydrate the lyophilized fusobacteria cells. The fusobacteria was mixed 
with dilution media by pipetting up and down. Once mixed, the entire suspension was withdrawn 
and transferred back to the original dilution tube containing 5 to 6 mL of dilution media.  
 
Growing Fusobacteria 
Fusobacteria suspension in quantities of 10 μL and 1 μL were pipetted onto blood agar plates and 
spread using plastic inoculating loops. These dilutions were each plated three times for a total of 
six plates. The plates were then placed in a 33 ℃ incubator inside of the anaerobic chamber 
agar-side up and incubated for 72 hours. After that time, 30 small colonies of fusobacteria were 
obtained using an inoculating loop and placed in a new tube containing 9 mL of dilution 
solution. Two milliliters of this dilution solution was used to create dilutions for determining 
color change with the CERVIS media (see Section 3.1-3.3), and the rest was taken outside of the 
anaerobic hood.  
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DNA Miniprep 
The fusobacteria suspension was then placed in a microcentrifuge tube 1 mL at a time and 
centrifuged at 7500 rpm for 1 minute. Following centrifugation, the supernatant was poured off 
into a waste beaker and an additional 1 mL of the suspension was added. This was repeated for 
the remainder of the fusobacteria mixture and the pelleted cells were stored in the 20 ℃ freezer 
until DNA miniprep could be completed. DNA miniprep was performed according to the Qiagen 
DNeasy Miniprep kit (cat. nos. 27104). 
 
Preparing Primers 
To prepare for the quantitative PCR, universal and ​Fusobacterium nucleatum​ specific-primers 
were first hydrated using the following protocol: primers in given tubes were spun down using 
microcentrifuge tubes, then molecular grade water was added at an amount relative to the primer 
amount in order to create a 100 µM primer stock. This solution was then allowed to sit at room 
temperature for 10 minutes. From the stock solution, a working 10 µM stock was created by 
diluting the original solution 1:10 in a sterile microcentrifuge tube.  
 
Section 3: Microscopy  
I.  ​Introduction 
There is a need for an alternative quantification method that creates a “known” quantity for 
generating an absolute standard curve. Our team chose microscopy (hemocytometry) as the best 
secondary quantification method for our qPCR experiments.  
II. Methods 
One hundred microliters of the initial fusobacteria dilution were pipetted onto a hemocytometer 
slide and placed under a Keyence microscope. From the nine 1mm x 1mm boxes on the 
hemocytometer slide, three 1mm x 1mm boxes were randomly chosen as a representative 
sample. In each of those three boxes, four 0.25mm x 0.25 mm boxes were randomly chosen 
among the sixteen boxes, and pictures were taken of the bacteria. The bacteria were counted and 
recorded. The bacteria counts for each of four 0.25mm x 0.25mm boxes were added together and 
multiplied by four, as the four boxes represented only one quarter of the total boxes in each 1mm 
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x 1mm grid. The sum of all of the three 1mm x 1mm was then calculated and multiplied by 
three, as these three boxes represented ⅓ of all the total boxes on the hemocytometer slide. 
Because the height of the hemocytometer slide is exactly 0.1mm, the total volume of the 
hemocytometer is (0.3mm x 0.3mm x 0.1mm) 0.9 mm​3​ (or 0.0009 mL). With the total number of 
bacteria and the total volume of liquid that bacteria were in, the concentration of the bacteria can 
be determined. The counts and sums of each of the boxes can be shown in the table below.  
III. Results  
Figure D: Microscopy Diagram 
 
Table K: Bacterial Counts Microscopy 
 1mm x 1mm Boxes 
0.25mm x 0.25 mm Boxes Box A Box B Box C 
1 288 263 252 
2 225 242 241 
3 228 221 276 
4 272 235 244 
Sum of 4 boxes 1013 961 1013 
Total estimate of bacteria in 
each 1mm x 1mm box 
1013 x 4 = 5252 961 x 4 = 3844 1013 x 4 = 5252 
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Sum of boxes A, B, C: 5252 +3844 + 5252 = 14,348 bacteria 
Estimate of entire grid: 14,348 x 3 = 43,044 bacteria 
Concentration of bacteria: 43,044 bacteria/0.0009 mL = 47,826,667 bacteria/mL 
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